MAP4K1 functions as a tumor promotor and drug mediator for AML via modulation of DNA damage/repair system and MAPK pathway

Qing Ling(Zhejiang Cancer Hospital), Jie Jin(Blood Center of Zhejiang Province)

EBioMedicine

June 21, 2021

10.1016/j.ebiom.2021.103441

Cited by 20

Related Papers

High PARP-1 expression predicts poor survival in acute myeloid leukemia and PARP-1 inhibitor and SAHA-bendamustine hybrid inhibitor combination treatment synergistically enhances anti-tumor effects

|EBioMedicine|2018|66

m<sup>6</sup>A‐dependent upregulation of DDX21 by super‐enhancer‐driven IGF2BP2 and IGF2BP3 facilitates progression of acute myeloid leukaemia

|Clinical and Translational Medicine|2024|20

miR-550-1 functions as a tumor suppressor in acute myeloid leukemia via the hippo signaling pathway

|International Journal of Biological Sciences|2020|18

Ganoderic acid A ameliorates non‑alcoholic streatohepatitis (NASH) induced by high‑fat high‑cholesterol diet in mice

|Experimental and Therapeutic Medicine|2022|14

Spermatogenesis associated serine rich 2 like plays a prognostic factor and therapeutic target in acute myeloid leukemia by regulating the JAK2/STAT3/STAT5 axis

|Journal of Translational Medicine|2023|14